BIOMARKER:

KRAS G12V

News alerts, weekly reports and conference planners

Entrez ID:

3845

Related biomarkers:

‹

›

KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) nivolumab + rigosertib Sensitive : C3 ESMO 2022 - 3wk	nivolumab + rigosertib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks nivolumab + rigosertib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	cetuximab Resistant: B - Late Trials cetuximab Resistant : B	cetuximab Resistant: B - Late Trials cetuximab Resistant : B
KRAS G12V	Ovarian Serous Adenocarcinoma	KRAS G12V	Ovarian Serous Adenocarcinoma	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2
KRAS G12V	Ovarian Cancer	KRAS G12V	Ovarian Cancer	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2	VS-6766 + VS-6063 Sensitive: C2 – Inclusion Criteria VS-6766 + VS-6063 Sensitive : C2
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
KRAS G12V	Spindle Cell Sarcoma	KRAS G12V	Spindle Cell Sarcoma	BAL3833 Sensitive: C3 – Early Trials BAL3833 Sensitive : C3	BAL3833 Sensitive: C3 – Early Trials BAL3833 Sensitive : C3
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
KRAS G12V	Hepatocellular Cancer	KRAS G12V	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	VS-6766 Sensitive: C3 – Early Trials VS-6766 Sensitive : C3	VS-6766 Sensitive: C3 – Early Trials VS-6766 Sensitive : C3
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	RGX-202 Sensitive: C3 – Early Trials RGX-202 Sensitive : C3	RGX-202 Sensitive: C3 – Early Trials RGX-202 Sensitive : C3
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	FOLFOX Resistant: C3 – Early Trials FOLFOX Resistant : C3	FOLFOX Resistant: C3 – Early Trials FOLFOX Resistant : C3
KRAS G12V	Lung Non-Squamous Non-Small Cell Cancer	KRAS G12V	Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	everolimus + VS-6766 Sensitive: C3 – Early Trials everolimus + VS-6766 Sensitive : C3	everolimus + VS-6766 Sensitive: C3 – Early Trials everolimus + VS-6766 Sensitive : C3
KRAS G12V	Lung Adenocarcinoma	KRAS G12V	Lung Adenocarcinoma	osimertinib Resistant: C4 – Case Studies osimertinib Resistant : C4	osimertinib Resistant: C4 – Case Studies osimertinib Resistant : C4
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	AZ 628 Resistant: D – Preclinical AZ 628 Resistant : D	AZ 628 Resistant: D – Preclinical AZ 628 Resistant : D
KRAS G12V	Colon Cancer	KRAS G12V	Colon Cancer	CDK9 inhibitor Sensitive: D – Preclinical CDK9 inhibitor Sensitive : D	CDK9 inhibitor Sensitive: D – Preclinical CDK9 inhibitor Sensitive : D
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	selumetinib + AZ 628 Sensitive: D – Preclinical selumetinib + AZ 628 Sensitive : D	selumetinib + AZ 628 Sensitive: D – Preclinical selumetinib + AZ 628 Sensitive : D
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	selumetinib Resistant: D – Preclinical selumetinib Resistant : D	selumetinib Resistant: D – Preclinical selumetinib Resistant : D
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D	JQ-1 Sensitive: D – Preclinical JQ-1 Sensitive : D
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	sunitinib Resistant: D – Preclinical sunitinib Resistant : D	sunitinib Resistant: D – Preclinical sunitinib Resistant : D
KRAS G12V	Ovarian Cancer	KRAS G12V	Ovarian Cancer	trametinib Sensitive: D – Preclinical trametinib Sensitive : D	trametinib Sensitive: D – Preclinical trametinib Sensitive : D
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	P1446A-05 Sensitive: D – Preclinical P1446A-05 Sensitive : D	P1446A-05 Sensitive: D – Preclinical P1446A-05 Sensitive : D
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	pembrolizumab Sensitive: D – Preclinical pembrolizumab Sensitive : D	pembrolizumab Sensitive: D – Preclinical pembrolizumab Sensitive : D
KRAS G12V	Pancreatic Cancer	KRAS G12V	Pancreatic Cancer	BMF-219 Sensitive: D – Preclinical BMF-219 Sensitive : D	BMF-219 Sensitive: D – Preclinical BMF-219 Sensitive : D

KRAS G12V

Associations